ACTU at a glance
ACTUATE THERAPEUTICS, INC. (ACTU, SEC CIK 1652935) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on November 13, 2026, an 8-K current report on October 30, 2026 and Form 4 insider filings as recently as November 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of September 30, 2026, 7 institutional investment managers tracked by SignalX reported holding ACTUATE THERAPEUTICS, INC. (ACTU) shares worth $466,000 in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by SCHMITT DANIEL M on October 28, 2026 of 140,844 shares at $0.35 per share.
- In the last 90 days, ACTU insiders reported 1 open-market purchase ($50K) and 0 open-market sales ($0) on Form 4, a net purchase of $50K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 1 buy · 0 sells
- Net +$50K
- 13F holders
- 7 funds
- $466K · −6 vs prior quarter
- Latest 8-K
- Oct 30, 2026
- Item 3.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no product sales generated
- Operating margin not applicable, operating loss $3,439,087 vs $5,472,378 YoY
- Worst expense category: R&D $1,811,601 vs $2,177,922, down $366,321
- Cash $2,101,816; operating cash use $12,373,256 for nine months
- October offering net proceeds $11,764,494; substantial doubt regarding going-concern status and additional funding needs
Risk Factors
- No material changes identified in the 10-Q Risk Factors section versus the 2025 10-K
- Liquidity risk: cash $2,101,816 and working-capital deficit $974,694, with substantial doubt about going-concern status
- Capital-markets risk: funding needs persist despite $11,764,494 October offering net proceeds
- Nasdaq compliance risk: noncompliance with $50 million MVLS and $1.00 minimum-bid requirements
- Clinical-development risk: elraglusib advancement depends on FDA or EMA feedback and patient enrollment
AI summary of the ACTU 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule
- Nasdaq deficiency: ACTU closed below the $1.00 minimum bid for 30 consecutive business days
- No immediate delisting: Common stock continues trading on Nasdaq Global Market under ACTU
Item 8.01: Other Events
- Actuate Therapeutics priced a securities offering on October 27, 2026
- Offering terms and proceeds require review of press release Exhibit 99.1
Item 1.01: Entry into a Material Definitive Agreement
- $9.96 million net proceeds from sale of 30,985,900 shares and warrants, providing near-term funding
- Offering structure: two shares plus one warrant at $0.71, implying substantial equity dilution for existing holders
Item EX-99.1: Item EX-99.1
- $11.0M gross equity financing, supporting working capital and general corporate purposes
- 30,985,900 shares issued with 15,492,950 immediately exercisable warrants, creating substantial dilution risk
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule
- Nasdaq MVLS deficiency after market value remained below $50 million from June 1–July 14, 2026
- Common stock remains listed and trading on Nasdaq Global Market under ACTU
AI summaries of ACTU 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ACTU
Don't miss the next ACTU filing
- Alerts as it files. A push when ACTU files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ACTU, by share count.
- Ask anything. An AI agent that reads every ACTU filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| BIOS Fund I, LP | A | Oct 28, 2026 | 47,972 | - |
| BIOS Fund I, LP | A | Oct 28, 2026 | 82,018 | - |
| BIOS Fund I, LP | A | Oct 28, 2026 | 368,304 | - |
| BIOS Fund I, LP | A | Oct 28, 2026 | 64,995 | - |
| BIOS Fund I, LP | A | Oct 28, 2026 | 194,984 | - |
| BIOS Fund I, LP | A | Oct 28, 2026 | 682,885 | - |
| SCHMITT DANIEL M | Buy | Oct 28, 2026 | 140,844 | $0.35 |
| BIOS Fund I, LP | A | Oct 28, 2026 | 87,743 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Operating Income | -$25.0M | -$25.2M | -$22.5M | |
| Net Income | -$24.7M | -$27.3M | -$22.2M | |
| Balance Sheet | ||||
| Total Assets | $3.0M | $9.3M | $14.0M | |
| Equity | -$99.6M | $104K | $7.9M | |
| ROE | 24.8% | -26189.1% | -280.5% | |
| Per Share | ||||
| EPS | $-17.24 | $-3.26 | $-1.06 | |
| Cash Flow | ||||
| Operating CF | -$21.6M | -$21.8M | -$19.2M | |
Source: XBRL data in ACTUATE THERAPEUTICS, INC. (ACTU)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate ACTU share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 7 | $466,000 |
| Q2 2026 | 13 | $1.2M |
| Q1 2026 | 15 | $3.1M |
| Q4 2025 | 11 | $7.2M |
| Q3 2025 | 11 | $5.1M |
| Q2 2025 | 10 | $3.8M |
| Q1 2025 | 7 | $831,000 |
| Q4 2024 | 1 | $114,000 |
- BlackRock−23.1K (-26%)
- Millennium Management−6.5K (-7%)
- Morgan Stanley−1.3K (-38%)
- Wells Fargo & Co−6 (-0%)
- AQR Capital Management−127.5K
- Goldman Sachs Group−35.5K
- JPMorgan Chase & Co−7.6K
- FMR LLC (Fidelity)−3.3K
- PNC Financial Services−2.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 75 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ACTU filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 13, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Nov 2, 2026 | - | - | - |
| 4 | Oct 30, 2026 | - | - | - |
| 8-K | Oct 30, 2026 | - | Analysis | - |
| 4 | Oct 30, 2026 | - | - | - |
| 4 | Oct 29, 2026 | - | - | - |
| 8-K | Oct 28, 2026 | - | Analysis | - |
| 10-Q | Aug 14, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Aug 14, 2026 | - | - | - |
| 8-K | Jul 17, 2026 | - | Analysis | - |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 8-K | May 22, 2026 | - | Analysis | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 10-Q | May 14, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 11, 2026 | - | Analysis | |
| 8-K | May 6, 2026 | - | Analysis | |
| 4 | Apr 1, 2026 | - | - | - |
| 4 | Apr 1, 2026 | - | - | - |
| 4 | Apr 1, 2026 | - | - | - |
| 10-K | Mar 26, 2026 | Dec 31, 2025 | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
- ACET · Adicet Bio IncPharmaceutical Preparations
ACTU SEC filings: frequently asked questions
Are ACTU insiders buying or selling?
In the last 90 days, ACTUATE THERAPEUTICS, INC. (ACTU) officers, directors and 10% owners reported 1 open-market purchase worth $50,000 by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold ACTU stock?
As of September 30, 2026, the largest ACTUATE THERAPEUTICS, INC. (ACTU) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($307,000), Millennium Management ($70,000), BlackRock ($51,000), State Street Corp ($17,000), Northern Trust ($17,000). 13F-HR reports are filed up to 45 days after each quarter ends.
What did ACTU report in its latest 8-K?
ACTUATE THERAPEUTICS, INC. (ACTU) filed an 8-K on October 30, 2026 reporting Item 3.01 (Notice of Delisting or Failure to Satisfy a Continued Listing Rule). Nasdaq deficiency: ACTU closed below the $1.00 minimum bid for 30 consecutive business days.
What are the latest ACTU SEC filings?
ACTUATE THERAPEUTICS, INC. (ACTU) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on November 13, 2026, an 8-K current report on October 30, 2026 and a Form 4 insider filing on November 2, 2026.
What is ACTU's SEC CIK number?
ACTUATE THERAPEUTICS, INC. (ACTU)'s SEC Central Index Key (CIK) is 1652935. EDGAR lists every ACTU filing under that number.
Ask anything about ACTU
The research agent reads ACTU's filings, financials, insider trades and 13F holders, then answers with sources.